Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Morepen Labs successfully raised Rs. 200 Crore through QIP
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Subscribe To Our Newsletter & Stay Updated
